Bayer Aktiengesellschaft

Ciba-geigy Corporation

Hans-Georg Heine

Thomas Glaser

Henning Sommermeyer

Rudolf Schohe-Loop

Bodo Junge

Klaus Urbahns

Reilinde Wittka

Jean-Marie-Viktor De Vry

Wolfgang Dompert

Willy Hartmann

Jean M De Vry

Siegfried Goldmann

Hartmund Wollweber

Hans-Joachim Knops

Jean Marie Viktor De Vry

Wilhelm Brandes

Hans Rudolph

Wilfried Draber

Karl-Heinz Scholz

Egbert Wehinger

Peter-Rudolf Seidel

Frank Mauler

Otto Behner

Armin Hubner

Rolf Dhein

Dieter Arlt

Pieter Ooms

Uwe Priesnitz

Joachim Schuhmacher

Alfred Pischtschan

Siegfried Raddatz

Dieter Habich

Arnold Paessens

Helmut-Martin Meier

Hanno Wild

Karl Fuhr

Wolfgang Bender

Jutta Hansen

Arno Friedl

Otto Bendszus

Reinhard Jork

Hans-Dieter Scharf

Herbert Frauenrath

Karl-Friedrich Neuhaus

Wolfgang Roben

Ervin Horvath

Jean-Marie Viktor De Vry

Wolfgang Kanhai

The invention relates to the use of 5-substituted pyridine- and hexahydroquinoline-3-carboxylic acid derivatives, some of which are known, for the production of medicaments, in particular for the treatment of cerebral disorders.

Use of 5-substituted pyridine and hexahydroquinoline-3 carboxylic acid derivatives for treating diseases of the central nervous system

The present invention relates to the new use of 1,2-bridged 1,4-dihydropyridines which are known in some cases, of the general formula (I) ##STR1## in which R.sup.1 to R.sup.4 and a have the meaning indicated in the description, processes for their preparation and their use as medicaments, as selective potassium channel modulators, in particular for the treatment of the central nervous system.

Use of 1,2-Bridged 1,4-dihydropyridines as medicaments

The present invention relates to new 2,3-bridged 1,4-dihydropyridines of the general formula (I), ##STR1## in which R, R.sup.1, R.sup.2, D and E have the meaning given in the description, processes for their preparation and their use as medicaments, preferably for treatment of the central nervous system.

2,3-bridged 1,4-dihydropyridines, and their use as medicaments

Triazaspirodecanone-methylchromans are prepared by reacting methylchromans, which are substituted on the methyl group by appropriate leaving groups, with triazaspirodecanones. The substances can be employed for the production of medicaments, in particular for medicaments for the control of disorders of the central nervous system.

Triazaspirodecanone-methylchromans

Use of 1,2-bridged 1,4-dihydropyridines as medicaments

Diseases characterized by disturbances of the serotoninergic system, psychoses and depression are treated by administration of an aminomethyl-chroman of the formula ##STR1##

2-aminomethyl-chromans effective in the treatment of psychoses and

The present invention relates to the use of 1,4-dihydropyridine-3,5-dicarboxylic acid esters, some of which are known, of the general formula (I) ##STR1## in which A and R.sup.1 -R.sup.3 have the meaning given in the description, as medicaments, in particular for treatment of the central nervous system, and new selected active compounds.

Use of 1,4-dihydropyridine-3,5-dicarboxylic acid esters as medicaments

The present invention relates to the new use of 1-alkyl-3,5-diacyl-1,4-dihydropyridines which are known in some cases, of the general formula (I) ##STR1## in which R.sup.1 to R.sup.4 have the meaning indicated in the description, processes for their preparation and their use as medicaments, as selective potassium channel modulators, in particular for the treatment of the central nervous system.

5-acyl-1,4-dihydropyridines

The benzisothiazolyl-substituted aminomethylchromans are prepared either by substituting the corresponding unsubstituted aminomethylchromans on the amine nitrogen or reacting the corresponding benzisothiazolylalkylamines with appropriate activated methylchromans or reacting the amine nitrogen of aminomethylchroman first with an appropriately substituted alkine and then hydrogenating. The benzisothiazolyl-substituted aminomethylchromans can be used as active compounds in medicaments, in particular in medicaments for the treatment of disorders of the central nervous system.

Benzisothiazolyl-substituted aminomethylchromans

Use of substituted 6-amino-4H-pyrans

Use of N-substituted phenothiazines

The substituted 4H-pyrans are prepared by reacting either aldehydes or ylidene compounds with suitably substituted .beta.-diketones. The substituted 4H-pyrans according to the invention are suitable as active compounds in medicaments, in particular for the treatment of disorders of the central nervous system.

Substituted 4H-pyrans

Dioxo-thiopyrano-pyridine-carboxylic acid derivatives and their use as

The invention relates to the use of acyl-substituted aminopyrans for the production of medicaments, in particular of medicaments for the treatment of disorders of the central nervous system.

Use of acyl-substituted aminopyrans

Azaheterocyclylmethyl-chromans of the formula: ##STR1## in which E represents an azaheterocyclyl group selected from the group consisting of: ##STR2## wherein R.sup.6 represents hydrogen, hydroxyl, halogen or phenyl; and

Azaheterocyclymethyl-chromans

Growing community of inventors

Krefeld, Germany

Hans-Georg Heine